Overview
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.
Description
The primary endpoint is 1-year local recurrence rate and disease-free survival. We planned to recruit 170 patients who diagnosed as perivascular hepatocellular carcinoma. The patients will be randomized into SBRT group and RFA group as 1:1 ratio.
Eligibility
Inclusion Criteria:
- Primary hepatocellular carcinoma or recurrent hepatocellular carcinoma after curative treatment.
- Unifocal tumor ≤5cm
- Closed to great vessels (diameter ≥3mm)
- ECOG score 0-1
- Child-Pugh grade A or B7
- Sufficient liver and kidney function
Exclusion Criteria:
- Vascular invasion
- Extra-hepatic metastasis
- Received TACE before
- Inflammation of local skin
- Dysfunction of liver, kidney or bone marrow.
- Concomitant other malignant tumor or HIV infection